10-QPeriod: Q1 FY2022

AbbVie Inc. Quarterly Report for Q1 Ended Mar 31, 2022

Filed May 6, 2022For Securities:ABBV

Summary

AbbVie Inc. reported strong financial results for the first quarter of 2022, with net revenues reaching $13.5 billion, a 4% increase year-over-year. This growth was driven by robust performance across its key portfolios, particularly in immunology, neuroscience, and aesthetics. Diluted earnings per share (EPS) stood at $2.51, reflecting healthy profitability despite certain non-cash charges like amortization of intangibles and other integration-related expenses. The company generated substantial operating cash flow of $4.9 billion, underscoring its operational strength and ability to fund its growth initiatives and return capital to shareholders. The company continues to strategically invest in its pipeline, with approximately 90 compounds in development, over 50 of which are in mid- to late-stage development. Key product highlights include continued strong growth for Skyrizi and Rinvoq in immunology, alongside solid contributions from Aesthetics brands like Botox Cosmetic and Juvederm. AbbVie also demonstrated a commitment to capital allocation by returning $2.5 billion to shareholders through dividends and repurchasing $1.1 billion in stock during the quarter, while also managing its debt levels.

Financial Highlights

55 data points
Beta

Revenue

$13.54B

70.1% Gross Margin

Net Income

$4.49B

33.2% Net Margin

EPS (Diluted)

$2.51

Total Assets

$143.21B

Cash & Equivalents

$6.10B

Free Cash Flow

$4.75B

Financial Statements
Beta
Revenue$13.54B
Cost of Revenue$4.05B
Gross Profit$9.49B
SG&A Expenses$3.13B
Operating Expenses$8.82B
Operating Income$4.72B
Interest Expense$548.00M
Net Income$4.49B
EPS (Basic)$2.52
EPS (Diluted)$2.51
Shares Outstanding (Basic)1.77B
Shares Outstanding (Diluted)1.78B

Key Highlights

  • 1AbbVie reported net revenues of $13.5 billion for Q1 2022, a 4% increase over the prior year, demonstrating continued top-line growth.
  • 2Diluted Earnings Per Share (EPS) of $2.51 indicate strong profitability, even after accounting for significant non-cash charges like amortization of intangible assets.
  • 3Operating cash flow of $4.9 billion highlights the company's robust operational efficiency and ability to generate significant cash.
  • 4Key growth drivers include strong performance in the Immunology portfolio with Skyrizi and Rinvoq, and double-digit growth in Aesthetics (Botox Cosmetic, Juvederm Collection).
  • 5The company returned $2.5 billion to shareholders via dividends and $1.1 billion through share repurchases, demonstrating a commitment to capital return.
  • 6Research and Development (R&D) expenses decreased by 10% year-over-year, while acquired IPR&D and milestones also saw a decrease, suggesting focused investment and potential efficiency gains.
  • 7The company is actively managing its debt, with notable repayments including $2.9 billion in senior notes and refinancing of a $2.0 billion term loan.

Frequently Asked Questions

AbbVie's net revenues of $13.5 billion were driven by strong performance across several key areas. The Immunology portfolio saw significant growth from Skyrizi (up 66%) and Rinvoq (up 57%). The Aesthetics segment also performed exceptionally well, with Botox Cosmetic up 35.5% and the Juvederm Collection up 27.5%. Other notable contributors include Venclexta (up 21.1%) and Ubrelvy (up 70%). While Humira sales saw a slight decline globally due to biosimilar competition, its U.S. sales remained stable, and growth in newer immunology drugs is offsetting this.

AbbVie's operating earnings were $4.7 billion. While R&D expenses decreased by 10%, Selling, General & Administrative (SG&A) expenses increased by 10% primarily due to litigation reserve charges and increased brand investment. The gross margin as a percentage of net revenues improved to 70% from 68% in the prior year, positively impacted by product mix and lower amortization of intangible assets. Diluted EPS was $2.51, which, while strong, included significant after-tax costs such as $1.6 billion for amortization of intangible assets and $148 million for litigation matters.

AbbVie demonstrated a strong commitment to returning capital to shareholders. In the first quarter of 2022, the company paid $2.5 billion in cash dividends, an increase from the prior year, and repurchased $1.1 billion of its stock under its authorized repurchase program. The company also actively managed its debt, repaying $2.9 billion in senior notes and refinancing a $2.0 billion term loan, reflecting a focus on deleveraging and optimizing its capital structure.

AbbVie highlighted progress across its therapeutic areas. In Immunology, Skyrizi received FDA approval for psoriatic arthritis, and Rinvoq saw approvals for atopic dermatitis and ankylosing spondylitis, alongside positive Phase 3 Crohn's disease data. In Oncology, Epcoritamab showed positive topline results in a Phase 1/2 trial for large B-cell lymphoma. The Aesthetics pipeline includes Phase 3 trials for BoNTE. In Neuroscience, Qulipta met its primary endpoint in a Phase 3 chronic migraine study, and Vraylar received an sNDA for adjunctive treatment of major depressive disorder.